What’s the Difference Between Compounded Semaglutide and Ozempic?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The difference that matters most is regulatory, not chemical. Ozempic is an FDA-approved finished drug product with a reviewed label, a manufacturing application and a defined indication set. Compounded semaglutide is a preparation made by a licensed pharmacy for an individual patient against a prescription, and as the FDA states, compounded drugs are not FDA approved — the agency does not review them for safety, effectiveness or quality before they are marketed. Everything else people compare — price, access, presentation — flows from that distinction. It is also why calling a compounded preparation a generic version of Ozempic describes nothing real: no approved generic of Ozempic exists.

What Approval Actually Certifies

An FDA approval is a finding, on a specific evidentiary record, that a product's benefits outweigh its risks for a defined population and purpose, and that the manufacturing process reliably produces what the label says. The Ozempic prescribing information is the output of that review: three indications in adults with type 2 diabetes, a boxed warning, contraindications, a full adverse reaction dataset and defined dosage forms.

Compounding sits under a different statutory framework. It exists so pharmacies can prepare a medication for a patient whose needs cannot be met by an approved drug. No premarket review of safety, effectiveness or quality attaches to the resulting preparation. That is not a criticism of compounding; it is the design of the category.

Presentation and Dosage Form Differ Concretely

The current Ozempic label defines specific presentations: multi-dose pens at 2 mg/3 mL delivering four doses of 0.25 mg and two of 0.5 mg or four doses of 0.5 mg, 4 mg/3 mL delivering four doses of 1 mg, and 8 mg/3 mL delivering four doses of 2 mg, plus single-dose prefilled syringes at 0.25, 0.5 and 1 mg per 0.5 mL.

A compounded preparation is not required to match any of those. It may be supplied differently, at different concentrations, with different measuring requirements. The FDA has specifically reported adverse events that may relate to dosing errors with compounded injectable semaglutide, including patients measuring and self-administering incorrect doses and clinicians miscalculating doses.

The Ingredient Question

This is the most under-discussed difference. The FDA is aware that some semaglutide products sold by compounders may be salt forms, including semaglutide sodium and semaglutide acetate. The agency states that these are different active ingredients than those used in the approved drugs, that it does not have information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.

It has also established a green-list import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, and has warned API distributors selling to compounders. "Same active ingredient" is therefore an assumption to verify with a specific provider, not a given.

Indications Belong to the Approved Product Only

Ozempic is indicated for glycemic control in adults with type 2 diabetes, for reducing major adverse cardiovascular event risk in adults with type 2 diabetes and established cardiovascular disease, and for reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It has no weight-management indication.

A compounded preparation has no indications at all in the regulatory sense, because it has no approved label. When people describe what compounded semaglutide "is for," they are borrowing from the approved products that share the active moiety, which is a reasonable clinical shorthand but not a regulatory equivalence.

Why It Is Not a Generic

A generic drug is approved through an abbreviated pathway on a showing of bioequivalence to a specific reference product, and it carries FDA approval. Neither Ozempic nor Wegovy has an approved generic. Compounded semaglutide has not been through that process and is not the product of it.

The FDA lists claims that a compounded drug is the same as an FDA-approved drug among its published telehealth red flags. That is a usefully blunt test: a provider making that claim is contradicting the agency directly.

How to Choose Between Them Honestly

If an approved product is available and affordable to you, the case for it is straightforward: reviewed manufacturing, defined presentations, a full label and an indication that matches your situation. If it is not accessible, a compounded preparation dispensed by a state-licensed pharmacy after a real clinical evaluation is a different category with different assurances, and that should be stated rather than obscured.

PlexusDx dispenses through licensed 503A compounding pharmacies following a clinical intake and a prescriber decision, and describes the category accurately: compounded semaglutide is not an FDA-approved finished product and is not a generic version of any approved brand.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic?

No. Ozempic is an FDA-approved finished drug product with reviewed manufacturing, a defined label and specific indications. Compounded semaglutide is prepared by a licensed pharmacy for an individual patient against a prescription and is not FDA approved; the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. The difference is regulatory, not just commercial.

Is compounded semaglutide a generic version?

No. A generic drug is FDA approved through an abbreviated pathway on a showing of bioequivalence to a specific reference product. Neither Ozempic nor Wegovy has an approved generic, and compounded semaglutide has not been through that process. The FDA lists claims that a compounded drug is the same as an FDA-approved drug among its published telehealth red flags.

Do compounded products use the same active ingredient?

That is a question to verify with the specific provider. The FDA is aware that some semaglutide products sold by compounders may be salt forms such as semaglutide sodium and semaglutide acetate, states these are different active ingredients from those used in approved drugs, and says it is not aware of any lawful basis for their use in compounding. It has also issued an import alert on certain GLP-1 ingredients.

What indications does compounded semaglutide have?

None in the regulatory sense, because it has no FDA-approved label. Ozempic's three indications are all in adults with type 2 diabetes: glycemic control, cardiovascular risk reduction in those with established cardiovascular disease, and reduction of kidney and cardiovascular outcomes in those with chronic kidney disease. Descriptions of what a compounded product is "for" borrow from approved labeling.

Are the presentations different?

They can be. The Ozempic label defines multi-dose pens at 2, 4 and 8 mg per 3 mL with specified dose counts, plus single-dose prefilled syringes at 0.25, 0.5 and 1 mg per 0.5 mL. A compounded preparation need not match any of those and may involve different concentrations or measuring steps. The FDA has reported adverse events that may relate to dosing errors with compounded injectable semaglutide.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.